A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Phase 1 Withdrawn
A Phase 1 Dose Escalation Study of IPI-493
Phase 1 Terminated
53 enrolled
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
80 enrolled
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
54 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Terminated
45 enrolled
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1 Completed
42 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Phase 1 Completed
Geldanamycin Analogue in Treating Patients With Advanced Cancer
Phase 1 Completed
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Phase 1 Completed
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
78 enrolled
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase 1 Completed
70 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Phase 1 Terminated
30 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
48 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Phase 1 Completed
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
Phase 1 Completed
50 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Phase 1 Completed
35 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Phase 1 Completed
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
Phase 1 Completed
63 enrolled
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Phase 1 Terminated
10 enrolled
IPi-504-01
Phase 1 Completed
18 enrolled